Understanding and interpreting vision safety issues with vigabatrin therapy.

@article{Plant2011UnderstandingAI,
  title={Understanding and interpreting vision safety issues with vigabatrin therapy.},
  author={Gordon T. Plant and Robert C. Sergott},
  journal={Acta neurologica Scandinavica. Supplementum},
  year={2011},
  volume={192},
  pages={
          57-71
        }
}
Vigabatrin is an irreversible inhibitor of γ-aminobutyric acid (GABA) transaminase. It is effective as adjunctive therapy for adult patients with refractory complex partial seizures (rCPS) who have inadequately responded to several alternative treatments and as monotherapy for children aged 1 month to 2 years with infantile spasms. The well-documented safety profile of vigabatrin includes risk of retinopathy characterized by irreversible, bilateral, concentric peripheral visual field… CONTINUE READING
1
Twitter Mention

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 100 REFERENCES

Vigabatrin and epilepsy: lessons learned.

  • Epilepsia
  • 2007
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Vigabatrin-associated visual field constriction: a review

M. Lawden
  • Optometry Pract 2006;7:1–16
  • 2006
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Epilepsy: Vigabatrin treatment and visual field loss

  • Nature Reviews Neurology
  • 2011
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL